@article{10902/4581,
year = {2014},
month = {3},
url = {http://hdl.handle.net/10902/4581},
abstract = {Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease associated with accelerated atherosclerosis and increased risk of cardiovascular (CV) disease. AS patients also display a high prevalence of features clustered under the name of metabolic syndrome (MeS). Anti-TNF- α therapy was found to be effective to treat AS patients by suppressing inflammation and also improving endothelial function. Previously, it was demonstrated that a short infusion of anti-TNF- α monoclonal antibodyinfliximab induced a rapid and dramatic reduction in serum insulin levels and insulin resistance along with a rapid improvement of insulin sensitivity in nondiabetic AS patients. The role of adipokines, MeS-related biomarkers and biomarkers of endothelial cell activation and inflammation seem to be relevant in different chronic inflammatory diseases. However, its implication in AS has not been fully established. Therefore, in this review we summarize the recent advances in the study of the involvement of these molecules in CV disease or MeS in AS. The assessment of adipokines and biomarkers of endothelial cell activation and MeS may be of potential relevance in the stratification of the CV risk of patients with AS.},
organization = {Acknowledgments. The authors thank Mrs. Susana Escandon and Isabel Castro Fernandez, nurses from the Rheumatology Outpatient Clinic, Ms. Pilar Ruiz, a nurse from the Hematology Division, and the members of the Biochemistry Department from Hospital Lucus Augusti/Xeral-Calde, Lugo, for their valuable help to undertake this study. This study was supported by the European Union FEDER funds and “Fondo de Investigación Sanitaria” (Grants PI06/0024, PS09/00748, and PI12/00060) (Spain). This work was also partially supported by RETICS Programs, RD08/0075 (RIER) and RD12/0009/0013, from “Instituto de Salud Carlos III” (ISCIII) (Spain). Fernanda Genre and Begona Ubilla are supported by funds from the ˜RETICS Program (RIER). Raquel Lopez Mejías is a recipient of a Sara Borrell postdoctoral fellowship from the Instituto de Salud Carlos III at the Spanish Ministry of Health (Spain).},
publisher = {Hindawi Publishing Corporation},
publisher = {Biomed Research International. 2014;2014:860651. Epub 2014 Mar 18},
title = {Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis},
author = {Genre, Fernanda and López Mejías, Raquel and Miranda Filloy, José Alberto and Ubilla García, Begoña and Carnero López, Beatriz and Blanco Alonso, Ricardo and Pina Murcia, Trinitario and González Juanatey, Carlos and Llorca Díaz, Francisco Javier and González-Gay Mantecón, Miguel Ángel},
}